By Sydney Kodatsky | Tuesday, July 24, 2018 - 9:57am
A healthcare research firm is recruiting patients who have been diagnosed with hereditary (inherited) thrombotic thrombocytopenic purpura (hTTP). hTTP represents about 1% of TTP cases and is characterized by inherited deficiency or abnormality of the ADAMTS 13 enzyme.
For more information and for participation instructions click here.
More information about the types of TTP can be found here.
NB: Mention of any treatment products associated with this study are provided for information only and their inclusion is not an endorsement of a particular product or company by Answering TTP Foundation.